Multifaceted Strategies for Hypertension Control in Low-Income Patients

Key Takeaways

• The trial reported 18-month changes in systolic blood pressure comparing the intervention and enhanced usual-care groups in low-income adults with hypertension.
• A low-cost, multifaceted, team-based care strategy—including protocol-based management, audit and feedback, health coaching, and home monitoring—was tested against enhanced usual care in a cluster-randomized design.
• Safety and implementation outcomes were reported, including similar serious adverse event rates and improved adherence in the intervention group.

A randomized trial in low-income adults with hypertension compared a low-cost, multifaceted care strategy with enhanced usual care for changes in systolic blood pressure from baseline to 18 months.

The intervention was presented as a pragmatic care model for blood pressure management rather than a single therapeutic or technology change. It included team-based care, protocol-based intensive blood-pressure management, blood-pressure audit and feedback, health coaching on lifestyle changes and medication adherence, and home blood-pressure monitoring. The study focused on whether this structured approach produced different blood-pressure findings at follow-up after randomization. Available details center on the low-income population, the intervention-versus–enhanced-usual-care comparison, and the follow-up outcome assessment. The trial's central question was how this care model compared with enhanced usual care in the reported blood-pressure findings.

Published in NEJM, the cluster-randomized study enrolled low-income adults with hypertension and compared the low-cost, multifaceted strategy with enhanced usual care. The intervention was described in broad care-delivery terms as a coordinated, low-cost approach applied through routine care rather than a narrowly defined treatment substitution. Enhanced usual care, which included physician education on hypertension guidelines, served as the reference for assessing follow-up blood-pressure outcomes. The reported design positioned enhanced usual care as the basis for the blood-pressure outcome analysis.

Investigators reported change in systolic blood pressure from baseline to 18 months as the trial's primary effectiveness outcome. At 18 months, systolic blood pressure decreased by −15.5 mm Hg in the intervention group and −9.1 mm Hg in the control group, for a between-group difference of −6.4 mm Hg (95% CI, −9.0 to −3.8; P<0.001). Blood pressure control was described as an endpoint within this framework. The findings therefore reflect a randomized comparison of systolic blood-pressure reduction between the intervention and enhanced usual-care groups.

Adverse-event findings and implementation context were also reported. Serious adverse events occurred in 20.9% of patients in the intervention group and 21.7% in the control group. The mean adherence summary score was 2.8 in the intervention group and 2.1 in the control group, with a between-group difference of 0.7 points (95% CI, 0.6 to 0.8; P<0.001). In the randomized trial, implementation context was described as relevant to a low-cost care model intended for routine practice. The available account remains centered on the blood-pressure outcomes and the enhanced usual-care comparison, with safety and implementation supported by reported data.